These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 24974806)

  • 1. Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study.
    Chieffo A; Buchanan GL; Parodi G; Versaci F; Bianchi RM; Valenti R; Saccà S; Mongiardo A; Span S; Migliorini A; Spaccarotella C; Reimers B; Antoniucci D; Indolfi C; Ferrari A; Maehara A; Mintz GS; Colombo A
    EuroIntervention; 2014 Dec; 10(8):916-23. PubMed ID: 24974806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
    Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
    Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT).
    Kim JS; Kim BK; Jang IK; Shin DH; Ko YG; Choi D; Hong MK; Cho YK; Nam CW; Hur SH; Choi JH; Song YB; Hahn JY; Choi SH; Gwon HC; Jang Y
    Am Heart J; 2012 Apr; 163(4):601-7. PubMed ID: 22520526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study.
    Nakamura D; Lee Y; Yoshimura T; Taniike M; Makino N; Kato H; Egami Y; Shutta R; Tanouchi J; Yamada Y; Hara M; Sakata Y; Hamasaki T; Nishino M
    EuroIntervention; 2014 Dec; 10(8):924-33. PubMed ID: 24602858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of vascular responses after different types of second-generation drug-eluting stents implantation detected by optical coherence tomography.
    Ohtani H; Kimura S; Sugiyama T; Hishikari K; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Kojima K; Sagawa Y; Hikita H; Ashikaga T; Takahashi A; Isobe M
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):177-186. PubMed ID: 27761750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study.
    Kim SJ; Lee H; Cho JM; Park CB; Kim W; Kato K; Yonetsu T; Kim CJ; Jang IK
    Coron Artery Dis; 2013 Aug; 24(5):431-9. PubMed ID: 23722649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months' follow-up: an optical coherence tomography study.
    Hashikata T; Tojo T; Namba S; Kitasato L; Hashimoto T; Kameda R; Shimohama T; Yamaoka-Tojo M; Ako J
    Heart Vessels; 2016 Feb; 31(2):206-11. PubMed ID: 25362579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial.
    Adriaenssens T; Dens J; Ughi G; Bennett J; Dubois C; Sinnaeve P; Wiyono S; Coosemans M; Belmans A; D'hooge J; Vrolix M; Desmet W
    EuroIntervention; 2014 Aug; 10(4):439-48. PubMed ID: 25138182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the performance of zotarolimus- and everolimus-eluting stents by optical coherence tomography and coronary angioscopy.
    Masawa T; Abe S; Toyoda S; Sakuma M; Nasuno T; Kageyama M; Tokura M; Koizumi S; Taguchi I; Inoue T
    Heart Vessels; 2016 Aug; 31(8):1230-8. PubMed ID: 26271923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
    Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
    Omar A; Torguson R; Kitabata H; Pendyala LK; Loh JP; Magalhaes MA; Satler LF; Suddath WO; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2014 Dec; 84(7):1053-60. PubMed ID: 24619969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent.
    Toledano Delgado FJ; Alvarez-Ossorio MP; de Lezo Cruz-Conde JS; Bellido FM; Romero Moreno MÁ; Fernández-Aceytuno AM; de Lezo Herrerosde Tejada JS; Pineda SO; Saint-Gerons JM; Pavlovic D
    Catheter Cardiovasc Interv; 2014 Nov; 84(5):720-6. PubMed ID: 24174291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
    Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus vs. biolimus A9-eluting stent implantation): a randomised controlled trial.
    Adriaenssens T; Ughi GJ; Dubois C; De Cock D; Onsea K; Bennett J; Wiyono S; Sinnaeve P; Coosemans M; Ferdinande B; Belmans A; D'hooge J; Desmet W
    EuroIntervention; 2016 Apr; 11(14):e1619-26. PubMed ID: 25420791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents.
    Guagliumi G; Musumeci G; Sirbu V; Bezerra HG; Suzuki N; Fiocca L; Matiashvili A; Lortkipanidze N; Trivisonno A; Valsecchi O; Biondi-Zoccai G; Costa MA;
    JACC Cardiovasc Interv; 2010 May; 3(5):531-9. PubMed ID: 20488410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
    Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schömig A; Kastrati A
    Cardiovasc Revasc Med; 2013; 14(2):84-9. PubMed ID: 23352095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation.
    Kim JS; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Aug; 28(6):1281-7. PubMed ID: 21858655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.
    Wijns W; Vrolix M; Verheye S; Schoors D; Slagboom T; Gosselink M; Benit E; Donohoe D; Knape C; Attizzani GF; Lansky AJ; Ormiston J;
    EuroIntervention; 2015 Apr; 10(12):1383-90. PubMed ID: 24801119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.